Short answer: for fat loss, neither has strong human evidence. Ostarine is the one with measured body-composition data: 3 mg a day for 86 days removed about 0.6 kg of fat and added 1.3 kg of lean mass vs placebo (Dalton 2011). Cardarine was never tested for fat loss in people; it improved blood fats and raised fat burning after a meal in 2-week trials (Risérus 2008), but its development was stopped after cancers in long-term animal studies (GSK letter, 2013). Users rate cardarine higher for fat loss and endurance; that is anecdotal.
| Cardarine (GW501516) | Ostarine (MK-2866) | |
|---|---|---|
| Type | PPAR-delta agonist (not a SARM) | SARM |
| Fat loss in people | Not measured | About −0.6 kg vs placebo in 86 days |
| Muscle | Not a muscle builder | +1.3 kg lean mass in 86 days (3 mg/day) |
| Blood fats | Triglycerides and LDL down, HDL up | HDL down 17–27% |
| Testosterone | No androgen-receptor action; not measured | Total testosterone down in older men |
| Main risk | Cancers in 2-year animal studies | Lower HDL; liver-enzyme rises; liver-injury case reports |
Source: Sarmguide compound database; Cardarine: Health Canada: GW501516 – Serious risks associated with use of unauthorized product (GSK letter, 24 May 2013) (2013).
See them side by side with sources in the compare tool.
Ostarine for fat loss
In the 86-day trial, ostarine at 3 mg a day reduced fat mass by about 0.6 kg vs placebo, similarly in men and women, while body weight did not change (Dalton 2011). Its main value on a cut is keeping muscle: in adults over 60 losing weight on semaglutide, 3–6 mg a day reduced lean-mass loss by 71% (company data, Veru 2025). The old claim that it works by raising basal metabolic rate was not measured. User reports put fat loss at up to 5% body fat in an 8-week cycle while dieting. More: ostarine fact sheet.
Cardarine for fat loss
In human trials of 2–12 weeks at 2.5–10 mg a day, cardarine improved blood fats; in one 2-week study it also raised fat burning after a test meal and cut liver fat by 20% (Risérus 2008). No human trial measured fat loss or weight loss, and the endurance boost users describe has only been shown in mice (Narkar 2008). User reports claim 7–8% body fat lost in 8 weeks with diet and exercise; that is anecdotal. The cancer findings in two-year rat and mouse studies are the reason GSK stopped developing it (SOT 2009). More: cardarine fact sheet.
Cardarine VS Ostarine for fat loss
On the evidence, the comparison is uneven: ostarine has a small, measured fat-loss effect and a measured muscle-sparing effect, with lower HDL and testosterone as the trade-off. Cardarine has better blood-fat results but no measured fat loss in people, and a long-term cancer signal in animals. The original author preferred cardarine for fat loss because it made cardio easier for him (anecdotal). Reader results for both are on cardarine before and after and ostarine before and after.
Conclusion
Cardarine vs ostarine for fat loss: ostarine has the human body-composition data (a modest fat drop, more lean mass), cardarine has user reports and blood-fat data but animal cancer findings. Many people stack the two; that combination has not been studied, and a man using both had severe liver and muscle damage (Kintz 2021). Read ostarine stacks for what is known about the combination, and get bloodwork before and after any cycle.
Frequently asked questions
Is cardarine or ostarine better for fat loss?
Neither has strong evidenceEvidence: Trial
Only ostarine has measured fat loss in people: about 0.6 kg vs placebo in 86 days. Cardarine improved blood fats but was never tested for fat loss in people; users rate it higher, which is anecdotal.
Is cardarine a SARM?
NoEvidence: Human data
Cardarine is a PPAR-delta agonist. It does not act on the androgen receptor; ostarine does.
Can you stack cardarine and ostarine?
Not studied togetherEvidence: Human data
Many people do, but the combination has not been studied. A man using both had severe liver damage and muscle breakdown.
Does cardarine suppress testosterone like ostarine?
Not expected; not measuredEvidence: Trial
Cardarine does not act on the androgen receptor, and its trials did not measure testosterone. Ostarine lowered total testosterone in older men.
Sources
- The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
- Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men
- Health Canada: GW501516 – Serious risks associated with use of unauthorized product (GSK letter, 24 May 2013)
- Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY (Semaglutide) for Weight Reduction (press release, 27 January 2025)
- AMPK and PPARdelta agonists are exercise mimetics
- Rat carcinogenicity study with GW501516, a PPAR delta agonist (Geiger et al., abstract 895) and Mouse carcinogenicity study with GW501516, a PPAR delta agonist (Newsholme et al., abstract 896), The Toxicologist 2009
- Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR- δ) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine)